HealthPhoto: Business StandardAstraZeneca Partners with Insitro for $40M AI Drug Discovery
AstraZeneca has partnered with AI biotech company Insitro to develop treatments for liver and heart diseases. The British drugmaker will pay $40 million upfront, with Insitro eligible for up to $1.46 billion in milestones plus royalties. The collaboration targets metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies using Insitro's AI platform to identify disease biology and advance drug candidates.
Business Standard·




